Covid-19 game changer, faster delivery, no cold storage and shipped USPA UPS FEDZ at home application.

Zosano Pharma Announces the Successful Formulation of a COVID-19 Vaccine Candidate on its Microneedle Patch System. The delivery technology has the capability to provide a room temperature stable, transdermal product to support a wide-spread deployment of a therapeutic solution.

Ideal Delivery

Coated microneedles that deliver directly to epidermal/dermal skin layers which may lead to an improved response and potential for dose sparing therapies.

One package, one dose

Room temperature stable, unit dose vaccine, delivered to the patient's door for at-home dosing

Stable: Zosano formulations are stable at room temperature, deployment using standard mail delivery systems

Easy disposal: Once applied the user would dispose of the unit in standard trash receptacles

Safe: The device prevents the user from inadvertently touching the microneedles and potentially removing some of the therapeutic.

Intuitive: Each patch is a unit dose, mitigating the need for a weight-adjusted calculation of dose, and preventing overdose or incorrect administration.

Proof of Concept: Successfully formulated and dosed >30 compounds of which 6 have advanced to clinical trials –including a Phase 1 trivalent vaccine.

Phase 1 clinical data for influenza vaccine showed that the microneedle coated tri-valent flu vaccine was comparable in immune response to the commercial IM injection.

Extensive clinical applications: Over 40,000 patch applications with no incidences of infection.$Pfizer(PFE)$